GEN-003

What it is

GEN-003 was a therapeutic vaccine — one meant to help people who already have HSV-2, not to prevent infection. It was a protein-subunit vaccine, meaning it used purified pieces of the virus rather than the whole virus or its genetic code. Specifically it combined a fragment of HSV-2 glycoprotein D (gD2ΔTMR) and a fragment of the viral protein ICP4, together with Matrix-M2, a saponin-based adjuvant (an ingredient added to strengthen the immune response).

Where it stands

GEN-003 reached Phase 2 (NCT02114060). In its dose-optimization trial, the better-performing doses reduced HSV-2 viral shedding and genital-lesion rates, and some of that effect persisted at 12 months. On its own terms, this was one of the more encouraging therapeutic-vaccine datasets in the field.

Genocea registered five GEN-003 trials in all (listed above). The last of them, a maintenance-dose study (NCT03146403), is recorded on the registry as terminated with the reason “2017 business decision to cease GEN-003 spending.”

Despite the Phase 2 results, Genocea Biosciences discontinued GEN-003 in September 2017, redirecting the company toward cancer immunotherapy rather than funding the large, expensive Phase 3 that would have been needed. No other developer has taken the program forward, so as of the date above it remains halted. GEN-003 is a useful reminder that a promising mid-stage result is not the same as an approved product — programs can end for business reasons, not only scientific ones.